Protalix BioTherapeutics Inc (PLX): Thinking this may see under the $. I'm...

BooDog · 2024-04-17T12:51:41.9430000Z

Thinking this may see under the $. I'm keeping this on the radar and have already started accumulating again.

Play Episode

7min

Proactive - Interviews for investors

Genflow Biosciences CEO welcomes new investment; outlines dog longevity trial

Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about a pivotal new direction for the company as it initiates a clinical trial focused on improving aging in dogs. Leire described the trial as a natural evolution from Genflow's previous success in mice, noting the commercial appeal of the canine market. “There is nothing to improve really the quality of life of our aging dogs,” he said, adding that the study meets a significant unmet need. The trial will run for one year, with six months of treatment followed by six months of assessment. It's being managed by independent contract research organisation Syngene. Leire emphasised the scientific rigour of the trial, which is controlled, randomised and includes both aesthetic and biological endpoints. These include coat quality, mitochondrial function, and methylation clocks — all of which have potential crossover value for human applications. Leire also highlighted the company’s differentiated approach compared to US competitors using repurposed drugs like metformin. Genflow, he said, is pursuing gene therapy with the potential for greater impact. The investment supporting the trial, although limited in size, is seen as a strategic vote of confidence, bringing in credible investors from outside the UK, including the US. Leire described the initiative as a major step that could generate near-term revenue and redefine the company’s biotech positioning. For more company updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future content. #GenflowBiosciences #GeneTherapy #DogAging #BiotechInvestment #LongevityResearch #Mitochondria #PetHealth #ClinicalTrials #AgingDogs #BiotechNews

Proactive - Interviews for investors

Fineqia International CEO unveils first DeFi yield ETP

Fineqia International Inc (CSE:FNQ, OTC:FNQQF) CEO Bundeep Singh Rangar talked with Proactive's Stephen Gunnion about launching the world’s first exchange-traded product (ETP) that deploys digital assets in yield-bearing decentralized finance (DeFi). Rangar explained the product's unique value, providing access to DeFi yield through a transparent, regulated security listed on the Vienna Stock Exchange. The Fineqia FTSE Cardano Enhanced Yield ETN (AV:YADA) is based on the Cardano network, a top ten cryptocurrency valued at over $35 billion, and allows investors to participate in DeFi activities such as borrowing, lending, and validating transactions, which generate fees. Unlike traditional ETFs and ETNs, Fineqia's product reinvests 80% of these yields back to investors, making it a truly innovative approach. Rangar highlighted the importance of partnering with FTSE Russell, a subsidiary of the London Stock Exchange, to ensure robust pricing data for this groundbreaking product. He added, "This is an icebreaker for what we want to do in the industry... We’re about being innovative and different." This collaboration sets a milestone for the ETP industry by combining blockchain technology and traditional finance, giving fund managers and retail investors easy access to decentralized finance through a familiar financial instrument. Visit Proactive's YouTube channel for more videos like this one, and don’t forget to give the video a like, subscribe to the channel, and enable notifications for updates! #Fineqia #DeFi #CryptoETP #DecentralizedFinance #Cardano #DigitalAssets #ETN #CryptoInvesting #Blockchain #FTSERussell

Proactive - Interviews for investors

Wrkr CEO on super compliance growth strategy

Wrkr Limited CEO Trent Lund talked with Proactive at the AIM's Small and Midcap Conference about the company’s strategy to simplify compliance through a deeply integrated digital platform. The ASX-listed company, trading under the ticker WRK, connects users, employers, and superannuation funds to streamline data accuracy and reduce friction in onboarding processes. “We do all the hard work and the heavy lifting so the business and the employee don’t have to,” said Lund. He explained that Wrkr verifies user credentials and automates data flows, reducing error and increasing trust. The system connects to major superannuation funds and payroll systems, holding accurate user information even during job transitions. Lund detailed Wrkr’s monetisation model, which aims to earn approximately $7 per user through microservices, including license checks and transactions. Current pilots, including one with major fund REST, are transitioning to production. Each super fund implementation takes about nine months and represents between $7 million and $14 million in annual annuity revenue once fully operational. Looking ahead, 2025 will be focused on large-scale implementation, with 2026 anticipated to generate higher consumption-based revenues. In 2027, Wrkr expects a significant uplift with the introduction of payday super legislation. #WrkrLimited #TrentLund #ASXWRK #Superannuation #ComplianceTech #FintechAustralia #PayrollIntegration #InvestorUpdate #PaydaySuper #DigitalTransformation #DataVerification #WorkforceAutomation

Proactive - Interviews for investors

EnWave expands footprint with commercial license in Japan and U.S. biopharmaceutical agreement

EnWave Corporation CEO Brent Charleton joined Steve Darling from Proactive to announce the company has signed a commercial license agreement with Hokkai Yamato Foods Japan, a leading producer of processed foods such as soups, furikake, and ochazuke. As part of the agreement, Hokkai Yamato has acquired a 10kW Radiant Energy Vacuum (REV™) machine to drive product development and support early-stage commercial production in Japan. This license grants Hokkai Yamato exclusive rights to use EnWave’s patented REV™ technology for the production of various food products within Japan. In return, Hokkai Yamato will pay royalties to EnWave, consistent with existing licensing agreements. EnWave will work closely with Hokkai Yamato to optimize product development and ensure long-term commercial success. In addition to expanding its presence in the Japanese food sector, EnWave has also signed a master service agreement with BioTechnique, a U.S.-based pharmaceutical contract manufacturer. This agreement lays the groundwork for BioTechnique to evaluate EnWave’s REV™ dehydration technology as a potential alternative to freeze-drying in biopharmaceutical applications. As part of the collaboration, BioTechnique will conduct paid testing of several liquid pharmaceutical products, drying them in vials using pilot-scale REV™ machinery at EnWave’s Innovation Center in Delta, British Columbia. If the results prove successful, BioTechnique may choose to acquire its own REV™ equipment to provide dehydration services directly to its network of leading pharmaceutical clients. #proactiveinvestors #enwavecorporation #tsxv #enw #DehydrationTech #VacuumMicrowave #RoyaltyBusinessModel #BluechipClients #FoodTech #BusinessNews #Investing #CEOInterview #Peru #Spain #Blueberry #Snacks #Royalties #TradeMission

Followers	231
Posts	21585
Boards Moderated	1
Alias Born	08/03/2006

Volume:	97,594
Day Range:	2.46 - 2.57
Bid:
Ask:
Last Trade Time:	11:24:24 AM EDT
Total Trades:	754

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

PLX Detailed Quote

Recent PLX News

More PLX News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent PLX News

Go Ad-Free